A novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidases

The successful development of bortezomib-based therapy for treatment of multiple myeloma has established proteasome inhibition as an effective therapeutic strategy, and both 20S proteasome peptidases and 19S deubiquitinases (DUBs) are becoming attractive targets of cancer therapy. It has been report...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Liu, Ningning, Liu, Chunjiao, Li, Xiaofen, Liao, Siyan, Song, Wenbin, Yang, Changshan, Zhao, Chong, Huang, Hongbiao, Guan, Lixia, Zhang, Peiquan, Liu, Shouting, Hua, Xianliang, Chen, Xin, Zhou, Ping, Lan, Xiaoying, Yi, Songgang, Wang, Shunqing, Wang, Xuejun, Dou, Q. Ping, Liu, Jinbao
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group 2014
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4050382/
https://ncbi.nlm.nih.gov/pubmed/24912524
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep05240
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares